Universitat Autònoma de Barcelona
The research leading to these results was conducted as part of the PROTECT Consortium (Pharmacoepidemiological Research on Outcomes of Thera-peutics by a European ConsorTium, http://www.imi-protect.eu) which is apublic-private partnership coordinated by the European Medicines Agency.The PROTECT project has received support from the Innovative Medicines Initiative Join Undertaking [IMIJU] (http://www.imi.europa.eu) under Grant Agreement no 115004, resources of which arecomposed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and European Federation of Pharmaceutical Industries andAssociations (EFPIA)companies'in kind contribution. The views expressed are those of the authors only.
The online version of this article (doi:10.1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users.
English
Drug utilisation; Cross-national comparison; Defined daily doses; Prescription rates; Antibacterials; Hospital; Ambulatory; Indication
SpringerPlus ; Vol. 4 (october 2015)
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
https://creativecommons.org/licenses/by/4.0/
